UK Cell And Gene Therapy Cdmo Market Size & Outlook
UK cell and gene therapy cdmo market, 2018-2030 (US$M)
Related Markets
UK cell and gene therapy cdmo market highlights
- The UK cell and gene therapy cdmo market generated a revenue of USD 199.6 million in 2023 and is expected to reach USD 1,000.5 million by 2030.
- The UK market is expected to grow at a CAGR of 25.9% from 2024 to 2030.
- In terms of segment, pre-clinical was the largest revenue generating by phase in 2023.
- Pre-clinical is the most lucrative by phase segment registering the fastest growth during the forecast period.
Cell and gene therapy cdmo market data book summary
| Market revenue in 2023 | USD 199.6 million |
| Market revenue in 2030 | USD 1,000.5 million |
| Growth rate | 25.9% (CAGR from 2023 to 2030) |
| Largest segment | Pre-clinical |
| Fastest growing segment | Pre-clinical |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Pre-clinical, Clinical |
| Key market players worldwide | Lonza Group Ltd, Catalent Inc, Cytiva, Samsung Electronics Co Ltd, Thermo Fisher Scientific Inc, Novartis AG ADR, Wuxi AppTec Co Ltd, AGC Inc, OmniAb Inc, Rentschler Biopharma SE, Charles River Laboratories International Inc |
Other key industry trends
- In terms of revenue, UK accounted for 4.0% of the global cell and gene therapy cdmo market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, UK cell and gene therapy cdmo market is projected to lead the regional market in terms of revenue in 2030.
- Italy is the fastest growing regional market in Europe and is projected to reach USD 448.8 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cell And Gene Therapy CDMO Market Scope
Cell And Gene Therapy CDMO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
UK cell and gene therapy cdmo market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell and gene therapy cdmo market will help companies and investors design strategic landscapes.
Pre-clinical was the largest segment with a revenue share of 66.23% in 2023. Horizon Databook has segmented the UK cell and gene therapy cdmo market based on pre-clinical, clinical covering the revenue growth of each sub-segment from 2018 to 2030.
The UK is one of the lucrative markets for pharmaceutical companies due to its extensive R&D scenario, presence of excellent early innovation medicine platforms, and numerous pharmaceutical clinical trials being undertaken to address the challenges posed by various diseases.
The presence of established players in the region, such as Lonza Group, Catalent, Inc., Piramal Pharma Solutions, Boehringer Ingelheim, Jubilant, and AbbVie Contract Manufacturing, actively involved in providing pharmaceutical CDMO services, is expected to contribute to market growth.
Reasons to subscribe to UK cell and gene therapy cdmo market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of UK cell and gene therapy cdmo market databook
-
Our clientele includes a mix of cell and gene therapy cdmo market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the UK cell and gene therapy cdmo market , including forecasts for subscribers. This country databook contains high-level insights into UK cell and gene therapy cdmo market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
UK cell and gene therapy cdmo market size, by by phase, 2018-2030 (US$M)
UK Cell And Gene Therapy CDMO Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
